3D Global Biotech (ROCO:6808) Marketable Securities: NT$466.8 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6808 3D Global Biotech Inc ROCO:6808
80 GF Score
Price NT$36.85
GF Value NT$36.31
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is 3D Global Biotech Marketable Securities?

3D Global Biotech ROCO:6808 -1.86% 80 Marketable Securities is NT$466.8 Mil as of Jun. 2026. GuruFocus rates ROCO:6808 with a GF Score™ of 80/100 and a GF Value™ of NT$36.31 (Fairly Valued). The stock has 6 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. 3D Global Biotech's Marketable Securities for the quarter that ended in Jun. 2026 was NT$466.8 Mil.

3D Global Biotech's annual Marketable Securities increased from Dec. 2023 (NT$144.2 Mil) to Dec. 2024 (NT$647.7 Mil) but then declined from Dec. 2024 (NT$647.7 Mil) to Dec. 2025 (NT$459.8 Mil).

3D Global Biotech  (ROCO:6808) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

3D Global Biotech Marketable Securities Related Terms

3D Global Biotech Marketable Securities Historical Data

* Premium members only.

The historical data trend for 3D Global Biotech's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

3D Global Biotech Marketable Securities Chart

3D Global Biotech Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only 212.80 192.90 144.20 647.74 459.80

3D Global Biotech Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 274.00 647.74 714.88 459.80 466.78
ROCO:6808
80GF Score
3D Global Biotech Inc ROCO:6808
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

3D Global Biotech Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of NT$466.8 Mil mean?
3D Global Biotech (ROCO:6808) has a Marketable Securities of NT$466.8 Mil as of Jun. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on 3D Global Biotech and its competitors.
Is 3D Global Biotech's Marketable Securities too high?
3D Global Biotech's current Marketable Securities is NT$466.8 Mil. Overall, 3D Global Biotech has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does 3D Global Biotech's Marketable Securities compare to VRTX and REGN?
3D Global Biotech's Marketable Securities of NT$466.8 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on 3D Global Biotech and its competitors. 3D Global Biotech's current Marketable Securities is NT$466.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 3D Global Biotech stock overvalued right now?
Based on GuruFocus' analysis, 3D Global Biotech (ROCO:6808) is currently considered Fairly Valued. The stock's GF Value™ is NT$36.31, compared to a current price of NT$36.85 — trading 1.5% above its estimated fair value. The current Marketable Securities is NT$466.8 Mil. 3D Global Biotech's overall GF Score™ is 80/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For 3D Global Biotech (ROCO:6808), the current Marketable Securities is NT$466.8 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is 3D Global Biotech (ROCO:6808) Overvalued in 2026?

Based on GuruFocus' analysis, 3D Global Biotech stock appears to be overvalued. The current stock price of NT$36.85 is trading 1.5% above its estimated GF Value™ of NT$36.31. GuruFocus considers 3D Global Biotech to be Fairly Valued.

Key valuation signals for ROCO:6808:

  • Marketable Securities: NT$466.8 Mil
  • GF Value™: NT$36.31 vs. price of NT$36.85 (1.5% above fair value)
  • GF Score™: 80/100 with 6 warning signs

No single metric tells the full story. See the ROCO:6808 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

3D Global Biotech Business Description

Address No.99, Section 1, Xintai 5th Road, 21st Floor -3, Xizhi District, New Taipei, TWN, 221
3D Global Biotech Inc is engaged in the research and development of high-end medical equipment and biological 3D printing technology and the sale of medical Materials and other related products.
80GF Score

Get the complete analysis for ROCO:6808

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$36.85
Price
NT$36.31
GF Value